Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02572167 · ClinicalTrials.gov registry record · Phase 1
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 93
- Enrollment target
NCT02572167 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 93 participants.
The verdict
NCT02572167, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 93 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL)
Interventions
- DRUG nivolumab
- DRUG brentuximab vedotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2015-10-31 |
| Est. Completion | 2021-10-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02572167
The ClinicalTrials.gov registry entry for NCT02572167 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which nivolumab is the first listed.
NCT02572167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02572167 about?
NCT02572167 is a clinical study titled "A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma". The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL)
What is the current status of trial NCT02572167?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 93 participants. The study started on 2015-10-31. Estimated completion is 2021-10-21.
What interventions are being tested in trial NCT02572167?
The interventions under investigation include: nivolumab (DRUG), brentuximab vedotin (DRUG).
Who is sponsoring clinical trial NCT02572167?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.